The ongoing #SputnikV post-registration clinical trial in Russia involves 40,000 volunteers, with clinical trials announced in the UAE, India, Venezuela and Belarus
The Russian Direct Investment Fund (RDIF) and the Gamaleya National Center for Microbiology and Epidemiology, supported by international partners, launched a campaign across all major social media platforms to provide up-to-date information and raise awareness about the Russian COVID-19 vaccine around the world. The campaign will use #SputnikV hashtag.
The social media campaign will focus on progress of #SputnikV clinical trials, production and mass vaccination in different countries. During the campaign, the Gamaleya Center scientists will tell the story behind the technology and creation of #SputnikV vaccine, while people who received the #SputnikV inoculation will share their personal experiences and thoughts.
#SputnikV is the world’s first registered vaccine based on a well-studied human adenoviral vector-based platform and currently ranks among top-10 candidate vaccines approaching the end of clinical trials and the start of mass production on the World Health Organization’s (WHO) list. Russia submitted applications to the WHO for accelerated registration and prequalification of #SputnikV.
As per releases, the ongoing #SputnikV post-registration clinical trial in Russia involves 40,000 volunteers, with clinical trials announced in the UAE, India, Venezuela and Belarus.
Kirill Dmitriev, CEO, Russian Direct Investment Fund commented, “Our social media campaign will focus on providing up-to-date information about our vaccine effort for global audience but beyond that it also aims to give mankind hope that they will soon be able to break free from the COVID-19 pandemic and go back to normal life without lockdowns and facemasks.”